Objective: To describe and analyze how investigators handled concurrent steroid intake in SLE clinical trials; to identify remaining methodological problems and to discuss potential solutions.
Methods: A review of the literature was performed in Medline to identify randomized controlled trials (RCT) in lupus published during the past decade. A set of criteria was defined a priori to analyze these trials covering different aspects of steroid use in RCTs with regard to eligibility, randomization, post-randomization steroid use, analysis and reporting.
Results: Seventeen trials met the inclusion criteria and were analyzed. Median sample size was 30, ranging from 10–71. In three trials corticosteroid application was the study intervention. Three reports did not address steroid use among study subjects at all. In seven trials steroid use was part of the eligibility criteria in some way. Of the trials that allowed concurrent steroid use, seven checked for equal distribution of baseline steroids. In some cases clinically relevant differences did not reach statistical significance as sample sizes were very small. In only one study was randomization stratified for steroid use. Instructions for post-randomization steroid use were specified in only 3 of 14 trials where steroids were not part of the intervention. In 11 RCTs concurrent steroid use was free or no information was provided. Steroid dosing during the intervention was reported as a secondary outcome measure in four trials.
Conclusions: As sample sizes are often small, simple randomization is not reliable to avoid relevant between-group differences in baseline steroids. The power of statistical testing for group differences is limited for the same reason. Stratified randomization is rarely used. Free concurrent steroid use during the intervention is frequently allowed in lupus RCTs despite the risk of bias. Better data and accepted standards for a priori specified steroid regimens in RCTs are highly warranted.
Gaubitz M , Seidel M , Kummer et al. Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus . J Autoimmun1998; 11; 495–501 .
2.
Eros B , Geher P , Gomor B , Czeizel AE . Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy). Eur J Obstetr Gyn Reprod Biol1998; 80: 75–78 .
3.
Alvarez-Nemegyei J , Cobarrubias-Cobos A , Escalante-Triay F , Sosa-Munoz J , Miranda JM , Jara U . Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study . Lupus1998; 7: 414–419 .
4.
Tsakonas B , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus; 19987: 80–85 .
5.
Pallis M , Lim KL , Gardner-Medwin JM , Robins RA , Powell RJ . Correlation between CD29 density on CD8+ lymphocytes and serum IgG in systemic lupus erythematosus . Lupus1997; 6: 379–384 .
6.
McGrath H , Martinez-Osuna P , Lee FA . Ultraviolet-Al (340–440 nm) irradiation therapy in systemic lupus erythematosus . Lupus1996; 5: 269–274 .
7.
Austin JS , Maisiak RS , Macrina DM , Heck LW . Health outcome improvements in patients with systemic lupus erythematosus using two telephone counseling interventions . Arthritis Care Res1996; 9: 391–399 .
8.
Merkel PA , Chang Y , Pierangeli SS , Convery K , Harris EN , Polisson RP . The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases . Am J Med1996; 101: 576–583 .
9.
Meinao IM , Sato EI , Andrade LE , Ferraz MB , Atra E . Controlled trial with chloroquine diphosphate in systemic lupus erythematosus . Lupus1996; 5: 237–241 .
10.
Maisiak R , Austin JS , West SG , Heck L . The effect of person-centered counseling on the psychological status of persons with systemic lupus erythematosus or rheumatoid arthritis: a randomized, controlled trial . Arthritis Care Res1996; 9: 60–66 .
11.
Van Vollenhoven RE , Engleman EG , McGuire JL . Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial . Arthritis Rheum1995; 38: l826–183l .
12.
Daltroy LH , Robb-Nicholson C , Iversen MD , Wright BA , Liang MH . Effectiveness of minimally supervised home aerobic training in patients with systemic rheumatic disease . Br J Rheumatol1995; 34: 1064–1069 .
13.
Bootsma H , Spronk P.Derksen R et al. Prevention of relapses in systemic lupus erythematosus . Lancet1995; 345: 1595–1599 .
14.
Hackshaw KV , Shi Y , Brandwein SR , Jones K , Westcott JY . A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus . J Rheum1995; 22: 462–468 .
15.
Peretz A , Cantinieaux B , Neve J , Siderova V , Fondu P.Effects of zinc supplementation on the phagocytic functions of polymorphonuclears in patients with inflammatory rheumatic diseases . J Trace Electrolyte1994; 8: 189–194 .
16.
Adachi J , Cranney A , Goldsmith CH et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss . J Rheum1994; 21: 1922–1926 .
17.
Williams HJ , Egger MJ , Singer JZ et al. Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus . J Rheum1994; 21: 1457–1462 .
18.
Euler HI-I , Guillevin L.Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus. An interim report of the Lupus Plasmapheresis Study Group . Ann Med Int1994; 145: 296–302 .
19.
Denburg SD , Carbolic RM , Denburg JA . Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus . Arthritis Rheum1994; 37: 1311–1320 .
20.
Scudeletti M , Puppo F , Lanza L et al. Comparison of two glucocorticoid preparations (deflazacort and prednisone) in the treatment of immune-mediated diseases . Eur J Chin Pharmacol1993; 45 (Suppl 1): S29–S34 .
21.
Boumpas DT , Austin HA III , Vaughan EM , Yarboro CH , Klippel JH , Balow YE . Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy . Ann Int Med1993; 119: 366–369 .
22.
Kaaja R , Julkunen H , Viinikka L , Ylikorkala O.Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin . Obstetrics Gyn1993; 81: 327–331 .
23.
Euler HH , Schroeder JO , Zeuner RA , Teske B.A randomized trial of plasmapheresis and subsequent pulse cyclophosphamide in severe lupus: design of the LPSG trial . Int J Artificial Organs1991; 14: 639–646 .
24.
Walton Al , Snaith ML , Locniskar M , Cumberland AG , Morrow WJ , Isenberg DA . Dietary fish oil and the severity of symptoms in patients with systemic lupus erythematosus . Ann Rheum Dis1991; 50: 463–466 .
25.
Clark WE , Dau PC , Euler HH et al. Plasmapheresis and subsequent pulse cyclophosphamide versus pulse cyclophosphamide alone in severe lupus: design of the LPSG trial. Lupus Plasmapheresis Study Group (LPSG). J Clin Apheresis1991; 6: 40–47 .
26.
The Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . N Engl J Med1991; 324: 150–154 .
27.
Chee YC . The mega shot . Singapore Med J1990; 31: 15–16 .
28.
Albert DA , Hadler NH , Ropes MW . Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus . Arthritis Rheum1979; 22: 945–954 .
29.
Fauci AS , Dale DC , Balow JE . Glucocorticosteroid therapy: mechanisms of action and clinical considerations . Ann Int Med1976; 84: 304–150 .
30.
Dixon RB , Christy NP . On the various forms of corticoid withdrawal syndrome . Am J Med1980; 68: 224–229 .
31.
Weinstein MC . Allocation of subjects in medical experiments . N Engl J Med1974; 291: 1278–1285 .
32.
Altman D , Dore CJ . Randomization and baseline comparisons in clinical trials . Lancet1985; 335: 149–155 .
